CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 140 enrolled
Drug / intervention
Oral L-Arginine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01105130
NCT01105130Phase 2Completed
CompareCT.gov

A Randomized Phase II Dose Finding Study of ArginMax for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated With Radiotherapy

Wake Forest University Health Sciences·interventional·Posted Apr 16, 2010·Updated Sep 28, 2021

In Brief

A Phase 2 clinical trial evaluating Placebo and Oral L-Arginine for Male Erectile Disorder and 2 related conditions. Completed, enrolled 140 participants across 1 site.

Detailed Summary

RATIONALE: L-arginine supplements may improve the quality of life and erectile function in men who are prostate cancer survivors. PURPOSE: This randomized phase II trial is studying how well L-arginine supplementation works with or without enzyme inhibitors in treating erectile function and quality of life of prostate cancer survivors previously treated with radiation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Erectile Disorder, Prostate Cancer, Radiation Toxicity
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2010
Enrollment StartOct 1, 2010
Primary CompletionFeb 4, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 16.2 years ago

Interventions

Placeboother

Given orally

Oral L-Argininedrug

Given orally 3 capsules ArginMax and 3 Placebo capsules

Oral L-Argininedrug

Patients will take 6 capsules of ArginMax twice daily